Zoetis Inc. A Stock
€109.26
Your prediction
Zoetis Inc. A Stock
Pros and Cons of Zoetis Inc. A in the next few years
Pros
Cons
Performance of Zoetis Inc. A vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Zoetis Inc. A | 0.650% | 2.476% | 3.859% | -27.092% | 1.770% | -31.369% | -17.252% |
| BioMarin Pharmaceutical Inc. | 0.190% | 7.811% | 13.150% | -16.876% | 6.837% | -46.297% | -19.365% |
| AbbVie Inc. | 0.630% | -2.051% | 4.600% | -0.157% | -2.749% | 35.135% | 120.351% |
| Biogen Inc. | -0.370% | -1.601% | 15.415% | 24.741% | 8.675% | -37.245% | -29.088% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When examining the financials of Zoetis (NYSE: ZTS), a leading company in the pharmaceutical industry, a preliminary review reveals a robust picture with consistent growth in total assets over the last three years. This growth is coupled with a stable increase in shareholder equity, indicating prudent financial management and a strong balance sheet foundation. A deeper dive into the detailed numbers should provide further insights into the organization's financial health, as well as potential areas of caution.
Growing Top Line: Zoetis has demonstrated a steady increase in total revenues, with the trailing twelve-month (TTM) revenue at approximately $8.37 billion. The year-over-year quarterly revenue growth of 7.4% signals a solid capacity for expanding their market presence and sales effectiveness.
EBITDA and Operating Margins: The EBITDA and operating margins are notable strengths, with a TTM EBITDA of around $3.47 billion and an operating margin of 37.1%. These numbers suggest efficient operational management and profitability.
Comments
News
Should You Buy Zoetis Before Feb. 12?
Zoetis (NYSE: ZTS) tanked after its November earnings release. Will history repeat itself pre-market on Feb. 12, when the animal healthcare company releases results for the fourth quarter of 2025
2 Healthcare Stocks Poised for a Comeback in 2026
Zoetis (NYSE: ZTS) and Regeneron Pharmaceuticals (NASDAQ: REGN) are two healthcare leaders that have lagged broader equities over the past 12 months, as both encountered headwinds that led to
